[1] Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs.Geneva, World Health Organization, 2008(WHO/HTM/TB/2008.392).
[2] Global tuberculosis control:surveillance,planning,fnancing. geneva, World Health Organization,2007(WHO/HTM/TB/2007.376).
[3] Gandhi NR,Moll A,Sturm AW,Pawinski R,Govender T,Lalloo U,Zeller K,Andrews J,Friedland G.Extensively drug-resistant tubercu-losis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa[J].Lancet,2006,368(9547): 1575-1580.
[4] 梅建,薛桢,沈鑫,沈国妙,桂晓红,沈梅,高谦.原发性耐药是耐药结核病产生的重要原因[J].中华结核和呼吸杂志,2006,29(2):75-78.
[5] 程志忠.耐多药肺结核患者相关因素分析[J].中国健康教育,2007,23(4): 308-309.
[6] 李丽,夏俊娣,张文华,董志云,于维琴.110株结核分枝杆菌对喹诺酮类药物的药敏试验分析[J].中国防痨杂志,2003,25(3):146-148.
[7] 肖和平.结核分枝杆菌耐氟喹诺酮类药物的严重性及其特点[J].结核病健康教育,2008.2:26-28.
[8] Sindelar G,Zhao X,Liew A,Dong YZ,Lu T,Zhou JF,Domagala J,Drlica K.Mutant prevention concentration as a measure of fluoroquinolone potency againstmy cobacteria[J].Antimicrob Agents Chemother, 2000, 44(12):3337-3343.
[9] Kim SJ,Hong YP,Lew WJ,Yang SC,Lee EG.Incidence of pulmonary tuberculosis among diabetics[J].Tuber lung Dis,1995,76(6):529-533.
[10] Jeon CY,Hwang SH,Mim JH,Prevots DR,Goldfeder LC,Lee H,Eum SY,Jeon DS,Kang HS,Kim JH,Kim BJ,Kim DY,Holland SM,Park SK,Cho SN,Barry CE,Via LE.Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital[J].Clin Infect Dis,2008, 46(1):42-49.
|